Treatment of secondary central nervous system lymphoma with intrathecal rituximab, high‐dose methotrexate, and R‐DHAP followed by autologous stem cell transplantation: results of the HOVON 80 phase 2 study

    loading  Checking for direct PDF access through Ovid

Abstract

Abstract unavailable for this article.

Related Topics

    loading  Loading Related Articles